綠葉製藥(02186.HK)擬發行1億美元5.85%利率2025年到期可轉換債券及5000萬美元5.85%利率2025年到期可轉換債券
格隆匯10月23日丨綠葉製藥(02186.HK)發佈公吿,2024年10月22日,公司作為發行人與認購人(即Kale Asset Holding Ltd)訂立認購協議。根據認購協議(其中包括),公司已附條件同意根據認購協議所列若干條件向認購人發行,且認購人亦已附條件同公司商定根據認購協議所列若干條件認購和支付債券(本金總額為1億美元於2025年到期的5.85%利率可轉換債券及本金總額為5000萬美元於2025年到期的5.85%利率可轉換債券)。
債券可依照條款和條件轉換成轉換股份。如果債券全部按每股股份的初步換股價3.672港元進行轉換、並且不再發行其他股份,債券將轉換成約3.18億股股份,約佔公司截至本公吿日期已發行股本的8.44%,以及約佔公司截至本公吿日期在債券全部轉換下發行轉換股份後的經擴大已發行股本的7.78%。初步換股價為每股轉換股份3.672港元,較股份於10月22日(認購協議訂立日期)在聯交所所報收市價3.06港元溢價約20.00%。
預計A期債券及B期債券所得款項(各自在扣除委託費和其他相關開支後的)淨額分別約為9860萬美元及4930萬美元。集團擬將債券發行所得款項淨額用於置換現有債務;產品研發;及一般企業用途。轉換股份將根據一般授權進行配發及發行,轉換股份的發行無須取得股東的批准。公司將向新交所申請債券在新交所上市。公司亦將向聯交所申請轉換股份在聯交所上市和交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.